(OABI) OmniAb - Ratings and Ratios
Antibody, Therapeutics, Biotechnology, Research, Technology Platforms
OABI EPS (Earnings per Share)
OABI Revenue
Description: OABI OmniAb
OmniAb Inc. (NASDAQ:OABI) is a biotechnology company that licenses its proprietary discovery research technology to pharmaceutical and biotech companies, as well as academic institutions, to facilitate the development of therapeutics globally. The companys technology platform is designed to create and screen diverse antibody repertoires, identifying optimal antibodies and other target-binding proteins for partners drug development efforts.
The OmniAb platforms Biological Intelligence harnesses the power of the companys proprietary and engineered transgenic animals to generate optimized antibody candidates for human therapeutics. With a range of animal-based technologies, including OmniRat, OmniChicken, and OmniMouse, the company has established a robust pipeline for discovering novel antibodies. Additionally, the companys OmnidAb and OmniTaur platforms provide further capabilities for single-domain and cow-inspired antibodies, respectively.
From a business perspective, OmniAbs licensing model provides a potentially lucrative revenue stream, with partners likely paying significant upfront fees, milestones, and royalties on any resulting therapeutics. To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, partnership deal volume, and the number of therapeutics in development could be monitored. For instance, a rising number of partnerships and increasing revenue could indicate a strong pipeline and successful technology platform. Furthermore, tracking the progress of therapeutics discovered using OmniAbs technology through clinical trials could provide insight into the platforms efficacy and potential for future revenue.
To assess the companys financial health, metrics such as cash burn rate, operating expenses, and cash reserves could be analyzed. A high cash burn rate could indicate significant investment in research and development, potentially leading to future growth. Additionally, monitoring the companys cash reserves could provide insight into its ability to weather financial challenges and continue investing in its technology platform. With a market capitalization of $236.11M USD, OmniAbs financial situation and ability to execute on its business plan will be crucial to its success.
OABI Stock Overview
| Market Cap in USD | 219m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-11-02 |
OABI Stock Ratings
| Growth Rating | -87.4% |
| Fundamental | 30.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -69.6% |
| Analyst Rating | 4.75 of 5 |
OABI Dividends
Currently no dividends paidOABI Growth Ratios
| Growth Correlation 3m | -26.1% |
| Growth Correlation 12m | -87.7% |
| Growth Correlation 5y | -74.6% |
| CAGR 5y | -45.90% |
| CAGR/Max DD 3y | -0.52 |
| CAGR/Mean DD 3y | -0.77 |
| Sharpe Ratio 12m | -0.98 |
| Alpha | -78.27 |
| Beta | 0.720 |
| Volatility | 67.94% |
| Current Volume | 436.8k |
| Average Volume 20d | 378.1k |
| Stop Loss | 1.5 (-8.5%) |
| Signal | 0.32 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-63.5m TTM) > 0 and > 6% of Revenue (6% = 1.38m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 9.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 151.9% (prev 244.8%; Δ -92.86pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.11 (>3.0%) and CFO -31.5m > Net Income -63.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.77 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (106.1m) change vs 12m ago 4.62% (target <= -2.0% for YES) |
| Gross Margin 30.69% (prev 4.08%; Δ 26.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 7.28% (prev 6.44%; Δ 0.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -15.38 (EBITDA TTM -33.5m / Interest Expense TTM 3.11m) >= 6 (WARN >= 3) |
Altman Z'' -5.96
| (A) 0.12 = (Total Current Assets 47.6m - Total Current Liabilities 12.6m) / Total Assets 295.7m |
| (B) -0.46 = Retained Earnings (Balance) -135.5m / Total Assets 295.7m |
| (C) -0.15 = EBIT TTM -47.8m / Avg Total Assets 316.5m |
| (D) -4.03 = Book Value of Equity -135.5m / Total Liabilities 33.6m |
| Total Rating: -5.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 30.45
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield 14.00% = 5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda -0.74 = -2.50 |
| 6. ROIC - WACC -25.94% = -12.50 |
| 7. RoE -22.79% = -2.50 |
| 8. Rev. Trend -56.76% = -2.84 |
| 9. Rev. CAGR -18.80% = -2.50 |
| 10. EPS Trend -68.27% = -1.71 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of OABI shares?
Over the past week, the price has changed by +3.14%, over one month by -18.00%, over three months by -6.29% and over the past year by -64.04%.
Is OmniAb a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OABI is around 0.99 USD . This means that OABI is currently overvalued and has a potential downside of -39.63%.
Is OABI a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the OABI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.9 | 379.3% |
| Analysts Target Price | 7.9 | 379.3% |
| ValueRay Target Price | 1.1 | -32.9% |
Last update: 2025-09-05 04:54
OABI Fundamental Data Overview
CCE Cash And Equivalents = 41.6m USD (Cash And Short Term Investments, last quarter)
P/S = 9.5024
P/B = 0.8377
Beta = 0.938
Revenue TTM = 23.0m USD
EBIT TTM = -47.8m USD
EBITDA TTM = -33.5m USD
Long Term Debt = 21.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.84m USD (from shortTermDebt, last quarter)
Debt = 24.8m USD (Calculated: Short Term 3.84m + Long Term 21.0m)
Net Debt = 3.50m USD (from netDebt column, last quarter)
Enterprise Value = 202.0m USD (218.8m + Debt 24.8m - CCE 41.6m)
Interest Coverage Ratio = -15.38 (Ebit TTM -47.8m / Interest Expense TTM 3.11m)
FCF Yield = 14.00% (FCF TTM 28.3m / Enterprise Value 202.0m)
FCF Margin = 122.8% (FCF TTM 28.3m / Revenue TTM 23.0m)
Net Margin = -275.8% (Net Income TTM -63.5m / Revenue TTM 23.0m)
Gross Margin = 30.69% ((Revenue TTM 23.0m - Cost of Revenue TTM 16.0m) / Revenue TTM)
Tobins Q-Ratio = -1.49 (set to none) (Enterprise Value 202.0m / Book Value Of Equity -135.5m)
Interest Expense / Debt = 12.52% (Interest Expense 3.11m / Debt 24.8m)
Taxrate = 21.0% (US default)
NOPAT = -47.8m (EBIT -47.8m, no tax applied on loss)
Current Ratio = 3.77 (Total Current Assets 47.6m / Total Current Liabilities 12.6m)
Debt / Equity = 0.09 (Debt 24.8m / last Quarter total Stockholder Equity 262.1m)
Debt / EBITDA = -0.74 (Net Debt 3.50m / EBITDA -33.5m)
Debt / FCF = 0.88 (Debt 24.8m / FCF TTM 28.3m)
Total Stockholder Equity = 278.7m (last 4 quarters mean)
RoA = -21.48% (Net Income -63.5m, Total Assets 295.7m )
RoE = -22.79% (Net Income TTM -63.5m / Total Stockholder Equity 278.7m)
RoCE = -15.94% (Ebit -47.8m / (Equity 278.7m + L.T.Debt 21.0m))
RoIC = -17.14% (NOPAT -47.8m / Invested Capital 278.7m)
WACC = 8.79% (E(218.8m)/V(243.6m) * Re(8.67%)) + (D(24.8m)/V(243.6m) * Rd(12.52%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 66.67 | Cagr: -0.71%
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 79.43% ; FCFE base≈17.2m ; Y1≈21.3m ; Y5≈36.3m
Fair Price DCF = 3.81 (DCF Value 547.8m / Shares Outstanding 144.0m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: -56.76 | Revenue CAGR: -18.80%
Rev Growth-of-Growth: 51.79
EPS Correlation: -68.27 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 111.8
Additional Sources for OABI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle